Baxter International (BAX) Projected to Release Earnings on Thursday

Baxter International (NYSE:BAX) is expected to be posting its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect the company to post earnings of $0.5180 per share and revenue of $2.91 billion for the quarter. Baxter International has set its FY 2026 guidance at 1.950-2.150 EPS. Investors can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:30 AM ET.

Baxter International (NYSE:BAX) last posted its earnings results on Thursday, July 30th. The medical instruments supplier reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.19. The company had revenue of $2.96 billion during the quarter, compared to analyst estimates of $2.80 billion. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter last year, the business posted $0.59 EPS. On average, analysts expect Baxter International to post $2.04 EPS for the current fiscal year and $2.00 EPS for the next fiscal year.

Baxter International Stock Down 1.4%

NYSE BAX opened at $24.93 on Wednesday. The stock has a 50-day moving average of $24.73 and a two-hundred day moving average of $21.32. Baxter International has a 1-year low of $15.73 and a 1-year high of $30.00.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on BAX. Wolfe Research assumed coverage on shares of Baxter International in a research report on Tuesday, October 20th. They set a “peer perform” rating on the stock. Weiss Ratings cut shares of Baxter International from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, October 8th. Wall Street Zen downgraded shares of Baxter International from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. TD Cowen upped their target price on shares of Baxter International from $20.00 to $24.00 and gave the stock a “hold” rating in a research note on Monday, July 27th. Finally, Citigroup reduced their target price on shares of Baxter International from $28.00 to $27.00 and set a “neutral” rating on the stock in a report on Monday, October 5th. One investment analyst has rated the stock with a Buy rating, ten have assigned a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Reduce” and an average target price of $21.73.

Baxter International Company Profile

Baxter International Inc is a global medical products and healthcare technology company headquartered in Deerfield, Illinois. The company develops, manufactures and distributes products used in hospitals, clinics, ambulatory care centers and other healthcare settings.

Baxter’s portfolio has included intravenous therapies and administration systems, infusion pumps, connected-care technologies, surgical products, patient monitoring equipment and products used in medication preparation and delivery.